Prediction of Therapeutic Effects from One Course of TPF Chemotherapy for Advanced Hypopharyngeal Laryngeal Cancer.

Abstract

BACKGROUND:

In head and neck cancer, docetaxel, cisplatin and 5-fluorouracil (TPF) is often given in two or three cycles. The purpose of this study was to perform single-cycle TPF for chemoselection in patients with advanced hypopharyngeal laryngeal cancer.

PATIENTS AND METHODS:

The study included 56 patients with stage III/IV advanced hypopharyngeal/laryngeal squamous cell carcinoma. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS), TPF response rate, laryngeal sparing, and grade 3 or more adverse events.

RESULTS:

The median PFS was 34.8 months. The median OS was not evaluable. The response rate was 71%. The median laryngeal preservation period was not estimable. Grade 3 or 4 adverse events were reported in 46 patients.

CONCLUSION:

PFS rate in this study may have been improved by selecting surgical treatment for patients for whom chemoradiotherapy seemed less effective. One cycle of TPF in induction chemotherapy appeared effective for chemoselection.

• Authors: Ryo Maruyama, Isaku Okamoto, Hiroki Sato, Yasuaki Katsube, Takahito Kondo, Kiyoaki Tsukahara
• Journal: In vivo (Athens, Greece) (In Vivo) 2020 Sep-Oct Vol. 34 Issue 5 Pg. 2891-2896 ISSN: 1791-7549 [Electronic] Greece
• PMID: 32871829 (Publication Type: Journal Article)
• Copyright: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Taxoids
• Cisplatin
• Fluorouracil

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Carcinoma, Squamous Cell (drug therapy)
• Chemoradiotherapy
• Cisplatin (adverse effects)
• Fluorouracil
• Head and Neck Neoplasms
• Humans
• Laryngeal Neoplasms (drug therapy)
• Taxoids (therapeutic use)